Uniqure N.V. (NASDAQ: QURE) has announced the pricing of its public offering of 4,411,764 ordinary shares at a price of $17.00 per share. The company expects to receive gross proceeds of approximately $75 million from this offering.
The offering is expected to close on or about January 10, 2025, and the underwriters have been granted a 30-day option to purchase up to an additional 661,764 ordinary shares at the public offering price.
Leerink Partners, Stifel, and Guggenheim Securities are acting as the bookrunning managers for the offering, while Chardan and H.C. Wainwright & Co. are acting as the lead managers.
This offering is being made pursuant to Uniqure's automatically effective shelf registration statement on Form S-3 (file no. 333-284168) filed with the U.S. Securities Exchange Commission (SEC) on January 7, 2025.
Uniqure is a leading gene therapy company focused on advancing transformative therapies for patients with severe medical needs. The company has achieved approvals for its gene therapy for hemophilia B and is now progressing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.
The company has not only announced its pricing of the public offering but also provided an update on the aggregate gross proceeds and the participation of underwriters. The market has reacted to these announcements by moving the company's shares -9.8% to a price of $15.92. For more information, read the company's full 8-K submission here.
